ARF like GTPase 6 interacting protein 4Genealiases: SFRS20 · SR-25 · SRp25 · SRrp37
Q-omics provides the consensus-scored ARL6IP4 profile across patient tissues and cancer cell-line models. ARL6IP4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARL6IP4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ARL6IP4 protein abundance shows 18,944 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where ARL6IP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL6IP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL6IP4 survival associations across molecular data types. ARL6IP4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL6IP4 RNA expression–survival associations across cancer types. High ARL6IP4 expression shows unfavorable associations in KIRC, UVM, ACC and LIHC, but favorable associations in BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARL6IP4 RNA expression.
This table summarizes ARL6IP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARL6IP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL6IP4 shows higher tumor expression in COAD, KIRC, LIHC, CHOL, THCA and HNSC. The COAD box plot shows higher ARL6IP4 RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with ARL6IP4 in patient tissues and cancer cell lines. In patient samples, ARL6IP4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL6IP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
